5-Amino-1MQ Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT in fat cells, which in mice raises NAD+ and reduces fat gain. That is the accurate one-line description, and note the word mice. The entire promising story for this compound comes from animals and cells. There are no published human trials.

This guide covers what 5-Amino-1MQ is, how it works, what the research shows, what dosing looks like in research, and where the safety and regulatory questions sit. We keep the animal-versus-human distinction front and center, because it is the most important caveat for this particular compound.

At TrimRx, we believe understanding your options is the first step toward a more manageable health journey. If weight management is your goal, the free assessment quiz can show whether a personalized program fits. 5-Amino-1MQ sits outside that, and this article is educational only.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is 5-Amino-1MQ?

5-Amino-1MQ is a small synthetic molecule, not a peptide, despite often being sold in the peptide marketplace. Its full name is 5-amino-1-methylquinolinium. It is an orally bioavailable compound, which means it can be taken by mouth, unlike many injectable research compounds.

Quick Answer: 5-Amino-1MQ is a small molecule that blocks the enzyme NNMT (nicotinamide N-methyltransferase), not a peptide.

Its job is to inhibit an enzyme called nicotinamide N-methyltransferase, abbreviated NNMT. This enzyme is especially active in fat tissue. By blocking it, 5-Amino-1MQ changes how fat cells handle a key metabolic resource, which is the basis for its fat-loss reputation.

Calling it a peptide is a common but technical error. It is a small-molecule enzyme inhibitor. That distinction matters for understanding how it works, because its mechanism is enzyme inhibition, not the receptor or signaling activity typical of peptides.

How Does 5-Amino-1MQ Work?

5-Amino-1MQ works by inhibiting NNMT in fat cells, which has two linked effects. NNMT normally uses up methyl groups and produces a byproduct called 1-methylnicotinamide (MNA). When NNMT is blocked, less MNA forms and more nicotinamide stays available.

That spared nicotinamide can be converted into NAD+, a central molecule in cellular energy metabolism. Research shows 5-Amino-1MQ raises NAD+ specifically in fat cells without adding NAD+ precursors. In cell studies, NAD+ rose roughly 1.2 to 1.6 fold compared with untreated cells.

The combined result in models is reduced lipogenesis (fat storage) and a metabolic shift in adipocytes. So the compound does not burn fat directly. It reprograms fat-cell metabolism by removing an enzymatic bottleneck. We cover this in more depth in our 5-Amino-1MQ mechanism article.

What Does the Research Show?

The central study is Neelakantan et al. 2018, published in Biochemical Pharmacology. The investigators gave 5-Amino-1MQ to diet-induced obese mice at 20 mg/kg three times daily over 11 days and reported reversal of obesity: reduced body weight and white adipose mass without changes in food intake.

The mice also showed lowered plasma total cholesterol and smaller fat cells, consistent with increased lipid oxidation rather than eating less. The in vitro work found an IC50 around 1.2 micromolar, meaning the compound inhibits NNMT at low concentrations. Earlier genetic work had shown that knocking down NNMT made mice resistant to diet-induced obesity.

This is genuinely interesting preclinical data with a clean mechanism. The decisive caveat is that all of it is in mice and cells. As of 2026 there are no published human clinical trials of 5-Amino-1MQ, so none of these results have been confirmed in people.

What Are the Claimed Benefits?

The marketed benefits are fat loss, increased energy, and metabolic and anti-aging effects tied to higher NAD+. Here is the honest weighting.

Fat loss has the clearest preclinical basis, thanks to the Neelakantan obesity-reversal data and the NNMT-knockdown work. But preclinical basis is not the same as human proof. No trial has shown 5-Amino-1MQ causes weight loss in people.

Energy and anti-aging claims lean on the NAD+ story. NAD+ declines with age and is central to metabolism, so raising it sounds appealing. The connection from a fat-cell NAD+ increase to felt energy or slowed aging in humans is unproven and largely extrapolated.

Muscle and performance claims appear too, based on NAD+ biology and some experimental muscle work. These are speculative for humans. As a rule, the broader the benefit list, the thinner the human evidence behind the extra claims.

How Is 5-Amino-1MQ Used in Research?

Because it is orally bioavailable, 5-Amino-1MQ is usually sold as capsules or sometimes powder rather than as an injectable. That oral availability is one of its more distinctive features in the research-compound market.

There is no FDA-approved product and no official human dose. Vendor protocols often cite amounts in the range of tens of milligrams per day, sometimes around 50 mg, but these are not validated clinical doses. They are extrapolations and anecdotes. Our 5-Amino-1MQ dosing protocol article covers this with full caveats.

The animal dosing in the Neelakantan study, 20 mg/kg three times daily, does not translate directly to a human dose. Converting animal doses to humans is not a simple multiplication, and doing it casually is one of the common errors in the research-compound space.

What Are the Side Effects and Safety Concerns?

The honest answer is that the human safety profile is unknown, because there are no human trials. The mouse studies reported no obvious adverse effects at the doses used, but absence of obvious harm in short mouse studies is not a safety guarantee for people.

There are real theoretical concerns. NNMT and NAD+ metabolism are involved in many tissues, not just fat, so broadly inhibiting NNMT could have effects beyond the intended fat-cell target. The long-term consequences of chronically altering this pathway in humans are simply not characterized.

Product quality adds practical risk. Research-grade compounds vary in purity and can be mislabeled or contaminated, so what is in the capsule may not match the label. For a compound with zero human safety data, that uncertainty compounds the concern.

Is 5-Amino-1MQ Legal and FDA Approved?

5-Amino-1MQ is not FDA approved for any use. It is sold as a research chemical labeled not for human consumption. That status holds as of 2026.

This is different from compounded GLP-1 medications, which are prepared by licensed 503A pharmacies for individual patients under prescription with a real prescriber involved. 5-Amino-1MQ has no comparable regulated pathway. It is investigational, with no human trials behind it.

Buying or possessing research compounds sits in a legal gray area that varies by location, and using one outside a trial means accepting unknown risk. The not-for-human-use label reflects that no regulator has reviewed it for safety or effectiveness in people.

How Does 5-Amino-1MQ Compare to GLP-1 Medications?

The contrast is stark and worth stating directly. GLP-1 medications like semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) have large phase 3 trials in thousands of people, with documented weight-loss effects and known safety profiles. 5-Amino-1MQ has mouse data and no human trials.

They also work differently. GLP-1 drugs act on appetite and blood sugar through gut-hormone signaling. 5-Amino-1MQ works on fat-cell enzyme metabolism. The GLP-1 mechanism has been validated through to human outcomes. The 5-Amino-1MQ mechanism is validated only in animals and cells.

For anyone weighing options for weight management, this is the practical bottom line. One pathway has proven human results and medical oversight. The other is an interesting hypothesis that has not been tested in a single published human trial.

Key Takeaway: The key study is Neelakantan et al. 2018 in Biochemical Pharmacology, which reversed obesity in diet-induced obese mice.

What Is NNMT and Why Does It Matter?

NNMT, nicotinamide N-methyltransferase, is an enzyme that adds a methyl group to nicotinamide, producing 1-methylnicotinamide (MNA) and consuming a methyl donor called SAM in the process. It is especially active in fat tissue and the liver.

NNMT matters metabolically for two reasons. First, by consuming nicotinamide, it competes with the pathway that turns nicotinamide into NAD+, so high NNMT activity can lower NAD+ availability in a cell. Second, the methyl groups it uses connect it to broader methylation balance in the body.

Researchers have linked elevated NNMT activity in fat tissue to obesity and metabolic disease. A 2021 review by Liu and colleagues in BioMed Research International described NNMT roles in obesity and type 2 diabetes. This is why NNMT became a target: turning it down could, in theory, free up NAD+ and shift fat-cell metabolism in a favorable direction. 5-Amino-1MQ is one of the molecules designed to do exactly that.

What Is the NAD+ Connection?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to energy metabolism, present in every cell. It helps convert food into usable energy and participates in many cellular processes, including some tied to repair and aging biology. NAD+ levels tend to fall with age.

5-Amino-1MQ connects to NAD+ indirectly. By blocking NNMT, it stops nicotinamide from being diverted into MNA, leaving more nicotinamide for the salvage pathway that makes NAD+. The result in fat cells is a measurable rise in NAD+ without supplementing any NAD+ precursor directly.

This NAD+ angle is what links 5-Amino-1MQ to the broader longevity conversation. The honest caveat is that raising NAD+ in fat cells in a dish or a mouse is not the same as producing felt energy, slowed aging, or any other human benefit. The NAD+ story is mechanistically real and clinically unproven for this compound in people.

How Does 5-Amino-1MQ Differ From NAD+ Supplements?

5-Amino-1MQ and common NAD+ boosters like NMN or NR aim at the same outcome, higher NAD+, from opposite directions. NMN and NR supply precursors that feed into NAD+ production. 5-Amino-1MQ instead removes an enzyme that drains the precursor pool, by inhibiting NNMT.

The proposed advantage of the NNMT-inhibitor approach is targeting. Because NNMT is especially active in fat tissue, blocking it may raise NAD+ preferentially there, which fits the fat-loss goal. Precursor supplements raise NAD+ more broadly. Whether targeted is actually better in humans is unknown, since 5-Amino-1MQ has no human trials.

It is also worth noting that NMN and NR have at least some human studies behind them, even if their benefits are debated. 5-Amino-1MQ does not. So while the approaches are mechanistically related, their evidence bases differ, and neither has delivered the dramatic human outcomes the marketing often implies.

Who Might Be Interested in 5-Amino-1MQ and Why?

Interest in 5-Amino-1MQ clusters among people focused on fat loss, metabolic optimization, and longevity. The fat-loss crowd is drawn by the obesity-reversal mouse data. The longevity crowd is drawn by the NAD+ angle. The two overlap heavily in the biohacking community.

The appeal is understandable. A clean mechanism, an oral compound rather than an injection, and a story connecting fat metabolism to NAD+ all line up with what these audiences want. That alignment is part of why the compound spread quickly through peptide and supplement marketplaces.

The thing to hold onto is that appeal and evidence are different. The reasons people are interested are real, but none of them substitute for a human trial. Until 5-Amino-1MQ is tested in people, interest reflects a compelling hypothesis, not a demonstrated benefit. We think the honest move is to find the science interesting while keeping the evidence bar where it belongs.

What Does 5-Amino-1MQ Not Do?

It helps to be explicit about the limits. There is no human evidence that 5-Amino-1MQ causes weight loss, treats obesity, or improves any condition in people. The fat-loss data is entirely from mice and cells. Marketing that presents it as a proven fat-loss compound is overstating the evidence.

It is also not a replacement for proven weight management tools. GLP-1 medications have phase 3 trials and clear results. 5-Amino-1MQ has none of that, so framing it as an alternative to medically supervised treatment misrepresents where it stands.

And it is not a verified anti-aging compound. The NAD+ connection is mechanistically real but does not translate automatically into slowed aging in people. No human study has shown 5-Amino-1MQ extends healthspan or reverses aging markers. Being clear about these negatives is the best defense against marketing that stretches narrow animal findings into broad human promises.

How Should You Evaluate 5-Amino-1MQ Claims Online?

The most useful filter is to ask one question repeatedly: is this claim from a human study or an animal one. For 5-Amino-1MQ, the answer is almost always animal, because there are no published human trials. A page that presents fat loss as established fact is hiding that gap.

Separate mechanism from outcome. A vendor may correctly state that the compound raises NAD+ in fat cells, then imply you will lose weight and feel younger. The first part has cell and mouse support. The second is an unproven leap into human outcomes. Outcomes in people are what matter, and those require trials that do not yet exist.

Watch for fabricated specifics too. Invented percentages, made-up review counts, and fake testimonials are red flags for any compound. Honest coverage names the Neelakantan 2018 mouse study, the absence of human trials, and the investigational status. Coverage that hides those behind confident benefit claims is selling, not informing.

The Path Forward

5-Amino-1MQ is a compound with a clean mechanism and genuinely promising mouse data, paired with a complete absence of human evidence. The fat-loss story is real in rodents and untested in people. That gap is the whole story, and honest coverage has to keep it visible.

At TrimRx, we build our programs around interventions with large human trials and real medical oversight. GLP-1 medications are the clearest example. If weight management is your goal, the free assessment quiz is the place to start, and a licensed provider reviews your case. We follow the NNMT research with interest, and we will update this guide if human trials of 5-Amino-1MQ ever change what we can say.

Bottom line: 5-Amino-1MQ is investigational. It is not FDA approved and is sold only for research use.

FAQ

Is 5-Amino-1MQ a Peptide?

No, despite often being sold alongside peptides. It is a small synthetic molecule, 5-amino-1-methylquinolinium, that inhibits the enzyme NNMT. Its mechanism is enzyme inhibition, not the receptor signaling typical of peptides.

Does 5-Amino-1MQ Cause Weight Loss?

It reduced fat and body weight in obese mice in the Neelakantan et al. 2018 study, but there are no published human trials. So it has not been shown to cause weight loss in people. The fat-loss claim is preclinical, not proven in humans.

How Does 5-Amino-1MQ Raise NAD+?

By blocking NNMT in fat cells, it spares nicotinamide that would otherwise be used up, allowing more of it to be converted to NAD+. In cell studies NAD+ rose roughly 1.2 to 1.6 fold. This effect is shown in cells and animals, not confirmed in humans.

Is 5-Amino-1MQ FDA Approved?

No. As of 2026 it is not FDA approved for any condition. It is sold as a research chemical labeled not for human use, with no human clinical trials behind it.

Can You Take 5-Amino-1MQ by Mouth?

It is orally bioavailable, so it is usually sold as capsules rather than as an injectable, which is unusual among research compounds. Oral availability does not make it approved or proven safe in people.

Is 5-Amino-1MQ Safe?

The human safety profile is unknown because there are no human trials. Mouse studies reported no obvious adverse effects short-term, but that does not guarantee human safety, and broadly altering NNMT and NAD+ metabolism could have effects beyond fat tissue. Product-quality risks add further uncertainty.

How Is 5-Amino-1MQ Different From NMN or NR?

They aim at the same goal, higher NAD+, from opposite directions. NMN and NR supply precursors that feed NAD+ production. 5-Amino-1MQ instead blocks NNMT, the enzyme that drains the precursor pool. NMN and NR have some human studies, while 5-Amino-1MQ has none, so their evidence bases differ.

Why Do People Call 5-Amino-1MQ a Peptide?

It is a common mislabel. The compound is sold in the peptide marketplace alongside actual peptides, so the name sticks. Chemically it is a small molecule enzyme inhibitor, not a peptide. The distinction matters because its mechanism is enzyme inhibition, not peptide receptor signaling.

What Was the Main 5-Amino-1MQ Study?

Neelakantan et al. 2018 in Biochemical Pharmacology. It gave the compound to diet-induced obese mice and reported reduced body weight and fat mass without changes in food intake, alongside an in vitro IC50 around 1.2 micromolar for NNMT inhibition. It was a mouse and cell study, not a human trial.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.